Sarah Goldberg

12PUBLICATIONS
156CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|Mar 06, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.

Helena A Yu, Kwan Ho Tang, Aleksandra A Markovets

|Jun 04, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.

Jonathan W Riess, Adrianus J de Langen, Santiago Ponce

|Mar 06, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.

Sarah A Weiss, Dijana Djureinovic, Wei Wei

|Mar 06, 2025
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer.

Ioannis P Trontzas, Mengni He, Anna Wurtz

|Jul 24, 2024
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From <i>EGFR</i> and <i>ALK</i> Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).

Luke R G Pike, Emily Miao, Lillian A Boe

Pageof 2

Frequent Collaborators

4 joint publications

Byoung Chul Cho

4 joint publications

Jonathan W Riess

4 joint publications

Helena A Yu

4 joint publications

Zofia Piotrowska